Back to search

Article

Nasal foralumab treatment of PIRA induces regulatory immunity, dampens microglial activation and stabilizes clinical progression in non-active secondary progressive MS

2025-05-03

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> Progression independent of relapses (PIRA) is a major therapeutic challenge in multiple sclerosis (MS). Nasal anti-CD3 treats animal models of progressive MS by inducing regulatory T cells (Tregs) that suppress central nervous system (CNS) inflammation and lessen clinical disease. <h4>Methods</h4> Ten patients with non-active secondary progressive MS (naSPMS) that continued to...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
ec29e87c-9b54-5fcd-8bb3-b676b3c7c1d6
DOI
10.1101/2025.04.30.25326602
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Nasal foralumab treatment of PIRA induces regulatory immunity, dampens microglial activation and stabilizes clinical progression in non-active secondary progressive MSDOI 10.1101/2025.04.30.25326602
Nasal anti-CD3 mAb (Foralumab) dampens CD3+ T effector function and decreases NKG7 in COVID-19 through a mechanism involving GIMAP-7 and TGFb1Semantic proximity
Dynamics of spinal fluid immune cell alterations following cladribine tablet treatment in multiple sclerosisSemantic proximity
Intranasal Anti-CD3 Antibody Treatment Attenuates Post–COVID Neuroinflammation and Enhances Hippocampal Neurogenesis and Cognitive Function in MiceSemantic proximity
Radiolabeled dendrimer non-invasively tracks innate immune activation in multiple sclerosis mice after immunomodulatory therapySemantic proximity
A Window to New Insights on Progression Independent of Relapse Activity in Multiple Sclerosis: Role of Therapies and Current PerspectiveSemantic proximity
Targeted Therapy of Multiple Sclerosis: a Case for Antigen-specific TregsSemantic proximity
Caerulomycin A suppresses the differentiation of naïve T cells and alleviates the symptoms of experimental autoimmune encephalomyelitis.Semantic proximity
Interval reduction in MRI lesion burden in relapsing-remitting multiple sclerosis following an integrative alternative medicine regimen: a case reportSemantic proximity
Masitinib is an oral, brain penetrant inhibitor of microglial and mast cell activity with neuroprotective potential in progressive forms of multiple sclerosisSemantic proximity
Glial activity load on PET (GALP) reveals persistent ‘smoldering’ inflammation in MS despite disease modifying treatment: [F-18]PBR06 studySemantic proximity
Ocrelizumab Impairs the Phenotype and Function of Memory CD8+ T Cells: A 1-Year Longitudinal Study in Patients With Multiple Sclerosis.Semantic proximity
Elevated IgG levels induce an M2‑to‑M1 phenotypic shift in mucosal macrophages and restrict the growth of invasive sphenoid sinus pituitary adenomas.Semantic proximity
Select a neighboring publication to make it the new centre.